Pfizer to Shut Down Oligo Therapeutics Unit as Part of Restructuring

It was not immediately clear what impact the move would have on the programs overseen by the unit.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.